Novartis India Ltd (NOVARTIND) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Novartis India Ltd on NSE and BSE, with an AI summary of each filing.
Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026.
Rights Issue · 05 Nov 2026, 1:16 am
Evonile Pharma Approves INR 8.85 Billion Rights Issue Terms Evonile Pharma Limited has fixed 11th Nov'26 as the record date for its INR 8,847.54 million rights issue of 10,287,832 partly paid-up equity shares priced at INR 860 per share (5:12 ratio). Payment is structured with INR 645 on application and INR 215 on the first and final call. The issue opens on 19th Nov'26 and closes on 3rd Dec'26, with renunciation ending 27th Nov'26. Total outstanding shares will expand from 24,690,797 to 34,978,629 post-issue, with tentative listing scheduled for 9th Dec'26.
Outcome of the Board Meeting held today i.e. November 04, 2026
Outcome · 05 Nov 2026, 12:45 am
Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) approved the issuance of partly paid-up equity shares via a rights issue for up to ₹9,000 million. In its board meeting on 4th Nov'26, following prior approval on 8th Oct'26, the board cleared the payment schedule, proceed utilization, and the Letter of Offer for regulatory filing with BSE and SEBI. The Rights Issue Committee has been authorized to determine final terms, including the issue price, entitlement ratio, and record date.
Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026
Rights Issue · 05 Nov 2026, 12:38 am
Evonile Pharma Approves INR 8.85 Billion Rights Issue Terms and Record Date Evonile Pharma Limited has finalized the terms for its INR 8,847.54 million rights issue of 10,287,832 partly paid-up equity shares at INR 860 per share (INR 645 on application, INR 215 on final call). The entitlement ratio is set at 5:12, with the record date fixed for 11th Nov'26. The issue opens on 19th Nov'26 and closes on 3rd Dec'26, with on-market renunciation ending 27th Nov'26. Post-issue outstanding equity shares will expand from 24,690,797 to 34,978,629, with listing targeted on or around 9th Dec'26.
Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026.
Audio / Video · 04 Nov 2026, 11:25 pm
Evonile Pharma Releases Earnings Call Audio Recording for Q2 FY27 Evonile Pharma Limited (formerly Novartis India Limited) has made available the audio recording of its earnings conference call held on 4th Nov'26 via virtual mode. The call discussed the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. The recording is accessible to investors on the company's official website, following the investor presentation submitted to the BSE on 3rd Nov'26. The company confirmed that no unpublished price-sensitive information was shared during the interaction.
Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Financial Result · 04 Nov 2026, 5:38 am
Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification Evonile Pharma Limited (formerly Novartis India) clarified its total outstanding bank debt and financial indebtedness at ₹800 crore as of 30th Sep'26 with zero defaults. For Q2 ended 30th Sep'26, revenue from operations dropped 37.9% YoY to ₹560.5 million. The company posted a net loss of ₹775.4 million versus a profit of ₹242.2 million in Q2 FY26, impacted by an exceptional item of ₹682.6 million following the termination of distribution arrangements. It also capitalized ₹12,900.0 million in intangible assets for trademark acquisitions.
Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Press Release · 04 Nov 2026, 1:31 am
ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology Following ChrysCapital's acquisition of a controlling 70.68% stake, Evonile Pharma (formerly Novartis India) reported its Q2 FY27 and H1 FY27 results under a revamped direct-distribution business model. Q2 FY27 revenue from operations reached ₹56.1 crore, while operating EBITDA stood at -₹31.8 crore due to upfront investments and one-time transition costs. For H1 FY27, revenue stood at ₹159.9 crore with a net loss of ₹45.3 crore. Strategically, the company expanded beyond its core therapy areas by acquiring Minipress XL (cardiology) and entering into an ophthalmology in-licensing agreement.
Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026.
Investor Presentation · 04 Nov 2026, 1:14 am
Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition Evonile Pharma transitioned to an independent domestic model, establishing 20+ CFAs and 2,000+ stockists. Q2 FY27 revenue from operations declined 38% YoY to ₹56.1 cr from ₹90.3 cr in Q2 FY26 due to the business model shift. Operating EBITDA was -₹31.8 cr with a net loss of ₹77.5 cr, impacted by ₹15.4 cr in one-off transition expenses and ₹68.3 cr in exceptional items from promotion rights termination. H1 FY27 revenue stood at ₹159.9 cr with a ₹45.3 cr net loss.
Unaudited Financial Results for the Quarter and half year ended as on September 30, 2026
Financial Result · 04 Nov 2026, 12:53 am
Evonile Pharma Reports Q2 FY27 Results with Exceptional Loss Evonile Pharma posted a net loss of ₹775.4m for the quarter ended 30th Sep'26, down from a net profit of ₹242.2m YoY and ₹322.1m QoQ. Revenue from operations dropped 37.95% YoY to ₹560.5m. The performance was severely impacted by an exceptional item of ₹682.6m, primarily relating to ₹610.0m from the termination of distribution arrangements with a major customer. Additionally, the company acquired trademark assets for ₹12,900.0m and approved raising up to ₹9,000.0m via a rights issue.
Intimation of the Unaudited Financial Results along with the Limited Review Report for the Quarter and half year ended September 30, 2026
Outcome · 04 Nov 2026, 12:34 am
Novartis India Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 561 (-37.9% YoY | -46.0% QoQ) ■ EBITDA: -318 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -56.8 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -775 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -31.4 (Profit to Loss YoY | Profit to Loss QoQ)
Disclosure of the receipt of In-principle approval from the Stock Exchange i.e. BSE Limited in relation to the draft Letter of Offer.
Others (Uncategorized) · 01 Nov 2026, 7:54 pm
Evonile Pharma Receives BSE In-Principle Approval for ₹9,000 Million Rights Issue Evonile Pharma Limited (formerly Novartis India Limited) secured in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly paid-up equity shares aggregating up to ₹9,000.00 million. The company's Board of Directors and Rights Issue Committee will meet on 4th Nov'26 to approve the Letter of Offer and determine key issue terms, including the issue price, entitlement ratio, and record date.
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Letter of Offer and intimation ....
Intimation · 01 Nov 2026, 7:49 pm
Evonile Pharma Receives In-Principle BSE Approval for ₹9,000 Million Rights Issue Evonile Pharma Limited (formerly Novartis India Limited) received in-principle approval from BSE on 30th Oct'26 for its proposed rights issue of partly paid-up equity shares aggregating up to ₹9,000.00 million. The company scheduled meetings of its Board of Directors and Rights Issue Committee on 4th Nov'26 to consider and approve the Letter of Offer and finalize key terms, including the issue price, rights entitlement ratio, and record date.
Intimation of the Earnings call proposed to be held on November 04, 2026, at 02:30 PM IST
Intimation · 04 Nov 2026, 2:30 pm
Evonile Pharma Schedules Q2 & H1 FY27 Earnings Call for 4th Nov'26 Evonile Pharma Limited (formerly Novartis India Limited) will host an earnings conference call for investors and analysts on 4th Nov'26 at 2:30 PM IST. The management team, including CFO Bhagwat Singh Deora and President of BD, M&A and IR Jason D'Souza, will discuss the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. Pre-registration is accessible via DiamondPass, alongside universal India dial-ins (+91 22 6280 1488 / +91 22 7115 8869) and international access lines for Hong Kong, Singapore, the UK, and the USA.
Intimation for the appointment of Mr. Gagan Sharma as the Senior Management Personnel of the Company.
Change in Management · 26 Oct 2026, 10:21 pm
Evonile Pharma Appoints Gagan Sharma as Senior Management Personnel Evonile Pharma Limited (formerly Novartis India Limited) has designated Mr. Gagan Sharma, President – Specialty Business, as Senior Management Personnel effective 26th Oct'26. Sharma brings over 30 years of commercial pharmaceutical experience spanning business transformation, global product launches, portfolio management, and omnichannel strategies. Most recently, he served as Therapy Area Head for Gene Therapy, Immunology, and In-Market Brands at Novartis Healthcare Private Limited, where he was also a member of the India Leadership Team.
The Board of Directors of the Company Evonile Pharma Limited (formally known as Novartis India Limited) approved the raising of funds by way of Rights Issue at their Board Meeting held ....
Others (Uncategorized) · 09 Oct 2026, 12:40 am
Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million The Board of Directors of Evonile Pharma Limited (formerly Novartis India Limited) approved raising up to ₹9,000 million through a rights issue of partly paid-up equity shares with a face value of ₹5 each at its meeting on 8th Oct'26. The board constituted a Rights Issue Committee to finalize the issue terms, price, entitlement ratio, and record date. The fundraising remains subject to shareholder approval via postal ballot and statutory clearances. Additionally, the company launched its new corporate website under the name Evonile Pharma.
The Board of Directors of Evonile Pharma Limited (formally known as Novartis India Limited) has approved the raising of funds by way of Rights Issue at their Board Meeting held today i.e. ....
Rights Issue · 09 Oct 2026, 12:36 am
Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) approved raising funds up to ₹9,000 million via a rights issue of partly paid-up equity shares (face value ₹5 each) on 8th Oct'26, subject to regulatory and shareholder approvals via postal ballot. The Board constituted a Rights Issue Committee comprising MD & CEO Vikas Gupta, Non-Executive Director Dr. Jagriti Gupta, and Independent Director Shashank Sinha to determine key terms, including issue size, entitlement ratio, issue price, and record date. Additionally, the company launched its new corporate website.
Intimation of the Outcome of the Board Meeting held today dated October 08, 2026
Outcome · 09 Oct 2026, 12:31 am
Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) announced that its Board of Directors approved raising funds up to ₹9,000 million via a Rights Issue on 8th Oct'26. The capital raise will involve partly paid-up equity shares with a face value of ₹5 each, subject to statutory and shareholder approvals via postal ballot. The Board constituted a Rights Issue Committee to finalize key terms, including issue size, entitlement ratio, pricing, and record date.
Intimation of the Credit Ratings assigned by CARE Ratings Limited.
Others (Uncategorized) · 07 Oct 2026, 11:32 pm
CARE Ratings Assigns Credit Ratings to Evonile Pharma's Bank Facilities CARE Ratings Limited has assigned credit ratings to the bank facilities of Evonile Pharma Limited (formerly Novartis India Limited) on 7th Oct'26. The agency assigned a 'CARE A; Stable' rating for the company's long-term bank facilities. Additionally, its combined long-term and short-term bank facilities received a 'CARE A; Stable / CARE A2+' rating.
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2026 ,inter alia, to consider and approve the raising of funds through ....
Intimation · 08 Oct 2026, 5:30 am
Evonile Pharma Board to Consider Rights Issue on 8th Oct'26 Evonile Pharma Limited (formerly Novartis India Limited) announced that its Board of Directors is scheduled to meet on 8th Oct'26 to consider raising funds via a rights issue of equity shares with a face value of ₹5 each to eligible equity shareholders. The proposed capital raise remains subject to board approval and requisite statutory clearances. Meanwhile, the company's trading window for designated persons remains closed from 1st Oct'26 until 5th Nov'26, covering both the rights issue discussion and the Q2 financial results declaration.
Intimation regarding the Amendments to the Memorandum and Articles of Association of the Company
Others (Uncategorized) · 01 Oct 2026, 10:35 pm
Novartis India Renamed as Evonile Pharma Following MCA Approval Novartis India Limited has officially changed its corporate name to Evonile Pharma Limited, effective 1st Oct'26, following the receipt of a fresh Certificate of Incorporation from the Ministry of Corporate Affairs (MCA). The rebranding follows shareholder approval via a Special Resolution passed at the 78th Annual General Meeting on 24th Sep'26. Consequently, the company has amended the Name Clause of its Memorandum of Association and Articles of Association to reflect the new corporate identity across its regulatory and constitutional filings.
Intimation of the Change of Name of Company from Novartis India Limited to Evonile Pharma Limited pursuant to the Fresh Certificate of Incorporation dated October 01, 2026, issued by Ministry ....
Others (Uncategorized) · 01 Oct 2026, 9:56 pm
Novartis India Renamed to Evonile Pharma Following MCA Approval Novartis India Limited has officially changed its corporate name to "Evonile Pharma Limited" effective 1st Oct'26, following the receipt of a fresh Certificate of Incorporation from the Ministry of Corporate Affairs (MCA). The rebranding was executed after securing shareholder approval via a Special Resolution at the 78th Annual General Meeting on 24th Sep'26, along with requisite statutory approvals. Consequently, the company has amended the name clauses across its Memorandum of Association (MoA) and Articles of Association (AoA) to reflect the new corporate identity.
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 03 Nov 2026, 5:30 am
Novartis India Board Meeting Scheduled on 3rd Nov'26 for Q2 Earnings Novartis India Limited announced that its Board of Directors will meet on 3rd Nov'26 to consider and approve the unaudited financial results for the quarter and half year ended 30th Sep'26. Additionally, the insider trading window for designated persons, insiders, and connected persons will remain closed starting 1st Oct'26 and reopen 48 hours following the declaration and submission of the financial results to BSE Limited.
Intimation of the Voting Results and the Scrutinizers Report for the 78th Annual General Meeting of the Company held on Thursday, September 24, 2026.
Annual General Meeting · 26 Sept 2026, 4:22 am
Intimation of the proceedings of the 78th Annual General Meeting of Novartis India Limited held on September 24, 2026.
Annual General Meeting · 25 Sept 2026, 12:17 am
Intimation is hereby given that the Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum by Nuvama on Monday, September 28, 2026.
Intimation · 23 Sept 2026, 11:04 pm
Novartis India to Participate in Nuvama Emerging India CEO Forum Novartis India Limited informed BSE that company officials will participate in the Nuvama – Emerging India CEO Forum on 28th Sep'26 in Mumbai. The interaction will feature in-person 1x1 and group meetings with institutional investors and analysts. The company confirmed that no unpublished price-sensitive information (UPSI) will be disclosed during the sessions.
Intimation regarding the newspaper publication made regarding the Corrigendum filed dated September 18, 2026, for the Notice of 78th Annual General Meeting
Annual General Meeting · 21 Sept 2026, 7:56 pm